ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1169

Hippocampal Atrophy Is Associated with Anti-NR2 Antibodies in Patients with Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome

Maria B Lauvsnes1, Mona K Beyer2, Jan T Kvaløy3,4, Ole J Greve5, Simone Appenzeller6, Erna Harboe7, Anne B Tjensvoll8, Lasse G Gøransson7 and Roald Omdal9, 1Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, 2Department of Radiology and Nuclear medicine, Oslo University Hospital, National Hospital, Oslo, Norway, 3Research Department, Stavanger University Hospital, Stavanger, Norway, 4Department of Mathematics and Natural Sciences, University of Stavanger, Stavanger, Norway, 5Department of Radiology, Stavanger University Hospital, Stavanger, Norway, 6Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil, 7Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 8Department of Neurology, Stavanger University Hospital, Stavanger, Norway, 9Department of Internal Medicin, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: autoantibodies, central nervous system involvement and systemic lupus erythematosus (SLE), Imaging, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: Imaging of Rheumatic Diseases: Magnetic Resonance Imaging (MRI)

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Antibodies against the NR2 subtype of the NMDA-receptor (anti-NR2 antibodies) are detected in patients with systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (SS). It is known from murine lupus models that these antibodies can cause hippocampal atrophy and cognitive impairment when they gain access to the brain. Reduced hippocampal volumes have been described in both SLE and primary SS patients; but a link between anti-NR2 antibodies and hippocampal atrophy has never been described in humans until now.

Methods:

A population-based cohort of 50 SLE (all fulfilling the ACR criteria) and 50 primary SS patients (all fulfilling the AECG criteria) were clinically examined and cerebral MRI scanning performed. Anti-NR2 antibodies were measured in cerebrospinal fluid (CSF). We applied the SPM8 software and compared hippocampal volumes between patients with and without anti-NR2 antibodies.

Results:

16 % of the SLE patients and 12 % of the primary SS patients had anti-NR2 antibodies in CSF. Patients with anti-NR2 antibodies had less grey matter in their hippocampi compared to patients without these antibodies. There were no differences in grey matter volumes in other areas of the brain. Hippocampal grey matter volumes did not differ between the two total groups of SLE and primary SS patients, and there were no statistical significant interactions between groups and anti-NR2 antibodies. No effect on hippocampal volumes were found for presence of anti-phospholipid antibodies, disease duration, or present use of corticosteroids. 

Conclusion:

Less hippocampal grey matter is observed in SLE and primary SS patients with anti-NR2 antibodies compared to those without these antibodies. This indicates that anti-NR2 antibodies may cause neuronal death in humans, as previously demonstrated in mice with autoimmune disease.

Figure 1:

Clusters of voxels with GM loss in patients with anti-NR2 antibodies (p < 0.05, FWE corrected). The cluster color represents the statistical significance of GM decrease according to the gradation of the color bar.


Disclosure:

M. B. Lauvsnes,
None;

M. K. Beyer,
None;

J. T. Kvaløy,
None;

O. J. Greve,
None;

S. Appenzeller,
None;

E. Harboe,
None;

A. B. Tjensvoll,
None;

L. G. Gøransson,
None;

R. Omdal,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hippocampal-atrophy-is-associated-with-anti-nr2-antibodies-in-patients-with-systemic-lupus-erythematosus-and-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology